𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

✍ Scribed by Verstovsek, Srdan; Kantarjian, Hagop; Mesa, Ruben A.; Pardanani, Animesh D.; Cortes-Franco, Jorge; Thomas, Deborah A.; Estrov, Zeev; Fridman, Jordan S.; Bradley, Edward C.; Erickson-Viitanen, Susan; Vaddi, Kris; Levy, Richard; Tefferi, Ayalew

Book ID
121719759
Publisher
Massachusetts Medical Society
Year
2010
Tongue
English
Weight
542 KB
Volume
363
Category
Article
ISSN
0096-6762

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Evaluating the serial use of the myelofi
Evaluating the serial use of the myelofibrosis symptom assessment form for measuring symptomatic improvement : Performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial
✍ Ruben A. Mesa; Hagop Kantarjian; Ayalew Tefferi; Amylou Dueck; Richard Levy; Kri πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 264 KB πŸ‘ 1 views

## Abstract ## BACKGROUND: Symptomatic burden from constitutional symptoms, anemia, and splenomegaly‐related symptoms are common and morbidity inducing in patients with myelofibrosis (MF). The authors previously developed a MF‐specific instrument for capturing the burden of MF‐associated disease‐r